By Dr. Liji Thomas, MD A landmark global trial shows that one dose of the RSVPreF3 OA vaccine protects older adults against ...

Some assume pneumonia is an inevitable consequence of ageing, while others may not realise they are at risk, says infectious ...

Major study shows that adults with respiratory syncytial virus-associated acute respiratory infection face a 2.7-fold higher ...

The Advisory Committee on Immunization Practices (ACIP) has voted to expand the recommended use of GSK’s AREXVY (Respiratory ...

New studies on respiratory syncytial virus (RSV) in both adults and young children show that infections are linked to a ...

A study presented at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A single dose of the RSVPreF3 OA vaccine offers strong protection against RSV-related lower respiratory tract disease in ...

A recent study highlights the alarming increase in death risk associated with respiratory syncytial virus (RSV) among adults.

Roughly 8000 Brits died from respiratory syncytial virus infections last year, with tens of thousands likely clogging up ...

the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...